Abstract 173P
Background
This retrospective multicenter real-world study aims to compare outcomes reached by L and S second-line therapy in HCC patients treated with first-line AB.
Methods
The overall cohort included 891 HCC patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea) treated with AB in first-line setting between October 2018 and April 2022. A total of 472 (53.0%) patients had progressive disease after first-line therapy, of which 243 (51.5%) received a second-line treatment. Data from 137 patients were available for the analysis: 51 (37.2%) received S and 86 (62.8%) L.
Results
L second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; HR: 2.24) compared to S subgroup that reached a mOS of 14.3 months. After adjusting for positive clinical covariates at univariate analysis, multivariate analysis highlighted Albumin-Bilirubin (ALBI) 1 grade [p < 0.01; hazard ratio (HR): 5.23] and L second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factor for OS. Forest plot highlighted a positive trend in terms of OS in favor of patients treated with L second-line regardless of baseline characteristics before first-line therapy. In particular, L second-line subgroup had a better OS compared to S second-line subgroup in male patients, aged ≤ 70 years, with viral etiology, Barcelona Clinic Liver Cancer C stage, αfetoprotein < 400 ng/mL, Child-Pugh A, NLR < 3, ALBI 1 grade, performance status ≤ 1, presence of portal vein thrombosis. Regarding first-line treatment outcomes, L second-line subgroup achieved a median progression-free survival (mPFS) of 3.5 months, while S second-line subgroup reached a mPFS of 4.3 months without any significative difference (p 0.42; HR: 1.15). There was no difference in overall response rate (L 26.1% vs. S 19.8%; p = 0.29) and disease control rate (L 76.8% vs. S 66.4%; p = 0.71) between the two subgroups.
Conclusions
L second-line therapy is superior to S in HCC patients progressed to first-line AB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract